Trial reportBMC pediatrics2026
Effectiveness of serial C-reactive protein point-of-care testing in optimizing antibiotic treatment in neonates and children in Zanzibar: an open-label, individual randomized controlled clinical trial protocol.
Trial report in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionAntimicrobial resistance is increasing globally. Children are disproportionately affected due to the overuse and misuse of antibiotics which is linked to lack of prompt diagnostics for suspected bacterial infections, limited access to health care facilities and financial constraints. The C-reactive protein (CRP) point-of-care test (POCT) presents an opportunity for quick and cost-effective diagnosis to establish the likelihood of a bacterial infection. However, information on the effectiveness of point-of-care CRP testing in hospitalized children in Zanzibar, Tanzania is limited. METHODS AND ANALYSIS: This multicenter, open-label, individual randomized controlled trial with 28 days follow-up is conducted at four hospitals in Zanzibar. Well-appearing neonates at risk of early onset sepsis, neonates (0 - 28 days) with clinical signs of infection on admission and children (6 months - 12 years) with febrile illness and/or diarrhea on admission are eligible for participation if their caretakers provide informed consent. The hospitals are supplied with CRP POCT equipment as well as a training session on CRP interpretation to aid in the clinical evaluation and antibiotic management of neonates and children. The primary outcome is the duration of antibiotic treatment within 14 days of the admittance of included neonates and children in each study arm and days to relapse of infection (defined as reinstitution of antibiotics within 72 h after completion of treatment). ETHICS AND DISSEMINATION: The study is approved by the Zanzibar Health Research Ethics Committee Ref. No. ZAHREC/04/AMEND/DEC/2023/11. The findings from this study will be used to generate policy briefs and technical reports to inform rational antimicrobial prescriptions' clinical practices and guide future research. Findings will be presented at global conferences and published in peer-reviewed medical journals to foster access to wider communities within Tanzania and beyond.
trial registrationThis trial was registered with ISRCTN registry (ISRCTN25937092) on 22/01/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.